These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 9289251

  • 21. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
    Teo SK.
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
    [Abstract] [Full Text] [Related]

  • 22. Replacement of streptomycin by ethambutol in the intensive phase of tuberculosis treatment: no effect on compliance.
    Rabarijaona L, Boisier P, Ratsirahonana O, Razafinimanana J, Rakotomanana F, Ratsitorahina M, Ramarokoto H, Cauchoix B, Aurégan G.
    Int J Tuberc Lung Dis; 1999 Jan; 3(1):42-6. PubMed ID: 10094168
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.
    Harries AD, Gausi F, Salaniponi FM.
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):724-9. PubMed ID: 15182142
    [Abstract] [Full Text] [Related]

  • 25. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam.
    Lan NTN, Lademarco MF, Binkin NJ, Tung LB, Quy HT, Cĵ NV.
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):575-8. PubMed ID: 11409587
    [Abstract] [Full Text] [Related]

  • 26. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion.
    Sundaram V, Fujiwara PI, Driver CR, Osahan SS, Munsiff SS.
    Int J Tuberc Lung Dis; 2002 Mar; 6(3):238-45. PubMed ID: 11934142
    [Abstract] [Full Text] [Related]

  • 27. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA.
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [Abstract] [Full Text] [Related]

  • 28. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S, Deivanayagam CN, Rajasekaran S, Venkatesan P, Padmapriyadarsini C, Menon PA, Ponnuraja C, Dilip M.
    Natl Med J India; 2008 Jan; 21(1):3-8. PubMed ID: 18472696
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Long-term efficacy of full course intermittent short-course chemotherapy on new smear positive tuberculosis patients].
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Jun; 20(3):164-6. PubMed ID: 10072822
    [Abstract] [Full Text] [Related]

  • 31. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [Abstract] [Full Text] [Related]

  • 32. [Standardized controlled antitubercular therapy and results in 755 patients].
    Wiesner B, Cramer G, Hamel U, Roth G.
    Z Erkr Atmungsorgane; 1991 Dec; 177(1-2):71-5. PubMed ID: 1808855
    [Abstract] [Full Text] [Related]

  • 33. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
    Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA.
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
    [Abstract] [Full Text] [Related]

  • 34. Short-course treatment in pulmonary tuberculosis.
    Jindani A.
    East Afr Med J; 1975 Sep; 52(9):472-80. PubMed ID: 53135
    [No Abstract] [Full Text] [Related]

  • 35. Tuberculosis treatment: dangerous regimens?
    Rieder HL, Arnadottir T, Trébucq A, Enarson DA.
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract] [Full Text] [Related]

  • 36. [Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy].
    Xu WG, Gao Z, Fan BD.
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Feb; 26(2):74-6. PubMed ID: 12783655
    [Abstract] [Full Text] [Related]

  • 37. 4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
    Chan SL, Wong PC, Tam CM.
    Tuber Lung Dis; 1994 Aug; 75(4):245-50. PubMed ID: 7949069
    [Abstract] [Full Text] [Related]

  • 38. [Profile of the patients lost to treatment in the National Anti-Tuberculosis Program in Madagascar].
    Rakotomanana F, Rabarijaona LP, Ratsitorahina M, Cauchoix B, Razafinimanana J, Ratsirahonana A, Boisier P, Aurégan G.
    Sante; 1999 Aug; 9(4):225-9. PubMed ID: 10623869
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.